Cora Sternberg

Oct 1, 2024 | urotoday.com | Cora Sternberg

Read the Full Video TranscriptAlicia Morgans: Hi. I'm so happy to be here today with Professor Cora Sternberg, who is joining me from New York after a wonderful ESMO 2024 presentation, in which she discussed event-free survival, an analysis that linked this to overall survival in muscle-invasive bladder cancer. Thank you so much for being here with me today, Professor Sternberg. Cora Sternberg: Thank you very much. It's a pleasure to be here with you, you know that.

Apr 24, 2024 | urotoday.com | Cora Sternberg

Read the Full Video TranscriptAlicia Morgans: Hi, I'm so excited to be here today with Professor Cora Sternberg, who is joining me to talk about enfortumab vedotin. Its changing role in the landscape of treatment of urothelial carcinoma and how we can all work together to really feel comfortable using EV as a treatment for our patients. So thank you so much for being here with me today, Professor Sternberg. Cora Sternberg: Alicia, it's always a pleasure to be here with you.

Apr 22, 2024 | europeanurology.com | Fred Saad |E. David Crawford |Luke T Nordquist |Maha Hussain |Bertrand Tombal |Karim Fizazi | +10 more

AbstractAddition of darolutamide to androgen deprivation therapy (ADT) and docetaxel significantly improved overall survival (OS) in ARASENS (NCT02799602). Here we report on prostate-specific antigen (PSA) responses and their association with outcomes. ARASENS is an international, double-blind, phase 3 study in patients with metastatic hormone-sensitive prostate cancer (mHSPC) randomized to darolutamide 600 mg orally twice daily (n = 651) or placebo (n = 654), both with ADT + docetaxel.

Nov 13, 2023 | urotoday.com | Cora Sternberg

Read the Full Video TranscriptAlicia Morgans: Hi, I'm so excited to be here today with Professor Cora Sternberg, who is the Englander Institute for Precision Medicine Professor and here visiting from Cornell University. Thank you so much for being here. Cora Sternberg: It's a pleasure to be here as always. How are you? Alicia Morgans: I am well, thanks, and so excited to talk with you.

Aug 10, 2023 | futuremedicine.com | Maha Hussain |Cora Sternberg |Eleni Efstathiou |Karim Fizazi

Future OncologyAhead of PrintPlain Language Summary of PublicationOpen Access, , , , , , , , , , & AbstractWhat is this summary about? This is a summary of a research article originally published in the Journal of Urology. The PROSPER study involved men who had a type of advanced prostate cancer called non-metastatic castration-resistant prostate cancer (nmCRPC). In patients with nmCRPC, their prostate cancer keeps growing even after traditional hormone treatments.